6 completed. 4 Phase 2, 2 Phase 1.
By phase and status
Follow firsocostat: new trials by email Literature Review of firsocostat trials Research Report on firsocostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
Semaglutide, Firsocostat, Cilofexor - Nonalcoholic Steatohepatitis | Phase 2 | Completed | Gilead Sciences | 109 | 2019-07-29 | 2021-07-15 |
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
SEL, FIR, CILO - Nonalcoholic Steatohepatitis | Phase 2 | Completed | Gilead Sciences | 395 | 2018-03-21 | 2020-12-03 |
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
Firsocostat, Fenofibrate - Nonalcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Gilead Sciences | 74 | 2016-09-23 | 2020-12-17 |
Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
Firsocostat, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Gilead Sciences | 127 | 2016-08-08 | 2020-07-24 |
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
SEL, FIR, CILO - Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Completed | Gilead Sciences | 220 | 2016-06-13 | 2022-03-16 |
Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects
GS-0976, Placebo, 1-13C acetate - PD Effects of GS-0976 (NDI-010976) on Fractional DNL | Phase 1 | Completed | Gilead Sciences | 30 | 2015-08-01 | 2016-08-24 |
Conditions studied
Non-alcoholic Fatty Liver Disease (5)
Sponsors
Gilead Sciences (6)
Countries
United States (6) · New Zealand (2) · Australia (1) · Canada (1) · Hong Kong (1) · Puerto Rico (1)
Top investigators
Rob Myers, MD (1)
Results publications
PMID 29705265, PMID 30059671, PMID 33169409, PMID 34999207, PMID 35439567